IOL Chemicals and Pharmaceuticals share news and announcements
NSE: IOLCPBSE: 524164Pharmaceuticals & BiotechnologySmall Cap
Last close ₹164.14down ₹7.22 (4.21%)BSE ₹163.40
Share price at the NSE close on 23 Oct 2026. Previous close ₹171.36.
52-week range of traded prices to 23 Oct 2026
₹67.19Low, 16 Mar 2026₹224.00High, 7 Oct 2026
- Under NSE's long-term additional surveillance, stage I, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Next results date: the board meets on 30 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹4,818 Cr1,024th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 10 Aug 2026
- 28.7
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 20 May 2026
- 2.7
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.61%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 10 Aug 2026
- 9.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 10 Aug 2026
- 11.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 20 May 2026
- 0.07
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 31,10,55637.2% delivered
IOL Chemicals and Pharmaceuticals orders, deals and press releases
78 filed, newest first. Page 2 of 2.
Nov 2015
Oct 2015
Aug 2015
Jul 2015
Jun 2015
May 2015
Nov 2014
14 Nov · Business
Allotment Committee of the Board of Directors in its meeting held on November 14, 2014 allotted 10,00,000 equity shares of Rs. 10/- each to M/s Innova Marchantiles Limited, Non-Promoter on the exercise of option attached with the warrants allotted on July 4, 2014. Consequent upon the issue of the above 10,00,000 equity shares, the total paid-up capital of the company stands increased to 4,10,11,591 fully paid equity shares of Rs.10/- each.13 Nov · Business
Allotment Committee of the Board of Directors in its meeting held on November 13, 2014 allotted 7,00,000 equity shares of Rs. 10/- each to M/s Innova Marchantiles Limited, Non-Promoter on the exercise of option attached with the warrants allotted on July 04, 2014. Consequent upon the issue of the above 7,00,000 equity shares, the total paid-up capital of the Company stands increased to 4,00,11,591 fully paid equity shares of Rs. 10/- each.
Jun 2014
Dec 2013
Nov 2013
Dec 2012
May 2012
2 May · Business
Share Allotment Committee of the Board of Directors in its meeting held on May 02, 2012 allotted 4,34,500 equity shares of Rs. 10/- each to the shareholders of G Drugs and Pharmaceuticals Limited in terms of the Exchange Ratio 1 (one) equity share of the Company of the face value of Rs. 10/- each credited as fully paid up at par for every 20 (Twenty) fully paid up equity shares of Rs.10/- each held by such equity shareholders of the G Drugs and Pharmaceuticals Limited as sanction by BIFR Order dated March 15, 2012, which will be locked in for a period of three years from the date of allotment. Consequent upon the issue of the above 4,34,500 equity shares, the total paid-up capital of the company stands increased to 2,61,51,164 fully paid equity shares of Rs. 10/- each.
Apr 2012
Dec 2011
Dec 2010
Nov 2010